ストックスクリーナーアプリを入手
6.97
1.83%
-0.13
Immunic Inc (IMUX) 最新ニュース
Stocks fall sharply as Syndax trial fails and S... - Pluang
Seven new Immunic employees get stock options tied to 196,350 shares - Stock Titan
Form 4 Immunic Inc For: 28 September By Investing.com - Investing.com UK
Form 4 Immunic Inc For: 28 September By Investing.com - Investing.com Canada
Form 4 Immunic Inc For: 28 September By Investing.com - Investing.com India
Director at Immunic (IMUX) gets options at $10.12 a share - Stock Titan
New option grant tied to Immunic (IMUX) director - Stock Titan
Immunic announces resignation of director Duane Nash and board size reduction By Investing.com - Investing.com Australia
Immunic Director Dr. Duane Nash Resigns; Board Cut to Nine Members - minichart.com.sg
Form 8K Immunic Inc For: 11 September By Investing.com - Investing.com South Africa
Immunic announces resignation of director Duane Nash and board size reduction - Investing.com
Form 8K Immunic Inc For: 11 September By Investing.com - Investing.com Nigeria
Form 8K Immunic Inc For: 11 September By Investing.com - Investing.com Canada
Immunic announces resignation of director Duane Nash and board size reduction - Investing.com
Dr. Duane Nash resigns from Immunic board; board reduced to nine members - TradingView
Immunic director Duane Nash resigns, board shrinks to nine members - Bitget
H.C. Wainwright reiterates Immunic stock rating on MS drug progress By Investing.com - Investing.com Nigeria
Immunic, Inc. (IMUX) Presents at EFMC Medicinal Chemistry 2026 BaselSlideshow (NASDAQ:IMUX) 2026-09-10 - Seeking Alpha
IMUX Reiterated by Wedbush -- Price Target Maintained at $45 - GuruFocus
Why Is Immunic (NASDAQ:IMUX) Advancing Its MS Drug Program? - Kalkine Media
Stifel reiterates Immunic stock rating on MS drug potential By Investing.com - Investing.com Canada
Stifel reiterates Immunic stock rating on MS drug potential - investing.com
H.C. Wainwright reiterates Immunic stock rating on MS drug progress By Investing.com - Investing.com Canada
IMUX Reiterates by HC Wainwright & Co. -- Price Target Maintained at $22 - GuruFocus
Immunic, Inc. R&D Day Transcript - GuruFocus
IMUX: Pivotal Phase 3 data for vidofludimus calcium in relapsing MS expected by end of 2026 - TradingView
Immunic (NASDAQ: IMUX) plans Sept. 9 relapsing MS R&D webinar - stocktitan.net
Immunic hosts RMS R&D Day webinar, presents vidofludimus calcium program and forward-looking plans - TradingView
Small cap wrap: Immunic, Midnight Sun Mining, Purepoint Uranium... - proactiveinvestors.com.au
Immunic to host virtual R&D day on relapsing MS ahead of Phase 3 trial results - Pluang
Immunic to host virtual relapsing MS R&D Day on September 9 - Yahoo Finance
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 - PR Newswire
EQS-News: Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026boerse.de - boerse.de
Immunic to host virtual relapsing MS R&D Day on September 9 - Proactive financial news
Immunic names Chitrang Davé chief data and digital officer - thepharmaletter.com
Immunic Appoints Chitrang Davé as Chief Data and Digital Officer - Investing News Network
Immunic appoints Chitrang Davé as chief data and digital officer - Yahoo Finance
Immunic Appoints Chitrang Davé as Chief Data and Digital Officer - PR Newswire
Immunic appoints Chitrang Davé as chief data and digital officer - Proactive financial news
Immunic: Potent Under-The-Radar MS Lineup Set For A Rerating (NASDAQ:IMUX) - Seeking Alpha
Long term debt to total assets ratio of Immunic, Inc. – HAM:10V - TradingView
Discontinued operations of Immunic, Inc. – HAM:10V - TradingView
Wedbush initiates Immunic stock with Outperform rating By Investing.com - Investing.com Australia
IMUX Initiates Coverage On Wedbush -- Rating Set to Outperform - GuruFocus
Wedbush initiates Immunic stock with Outperform rating By Investing.com - Investing.com Nigeria
Wedbush initiates Immunic stock with Outperform rating - Investing.com
Wedbush initiates Immunic stock with Outperform rating By Investing.com - Investing.com Canada
Wedbush initiates Immunic stock with Outperform rating By Investing.com - Investing.com UK
Renaissance Technologies LLC Invests $1.02 Million in Immunic, Inc. $IMUX - MarketBeat
Immunic (NASDAQ:IMUX) Upgraded to "Hold" at Wall Street Zen - MarketBeat
4.22%
大文字化:
|
ボリューム (24 時間):